Vanguard Group Inc Alaunos Therapeutics, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.12 - $0.5 $39,249 - $163,539	327,078 Added 3.59%	9,438,762 $1.23 Million
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $18,944 - $28,637	-44,057 Reduced 0.48%	9,111,684 $4.65 Million
Q1 2023 May 15, 2023	BUY	$0.46 - $0.81 $3,680 - $6,480	8,000 Added 0.09%	9,155,741 $5.77 Million
Q4 2022 Feb 10, 2023	SELL	$0.5 - $261.0 $7,391 - $3.86 Million	-14,782 Reduced 0.16%	9,147,741 $5.95 Million
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $138,665 - $43 Million	-133,332 Reduced 1.43%	9,162,523 $15.8 Million
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $607,954 - $1.84 Million	-1,482,815 Reduced 13.76%	9,295,855 $11.5 Million
Q1 2022 May 13, 2022	SELL	$0.62 - $1.17 $530,118 - $1 Million	-855,030 Reduced 7.35%	10,778,670 $7.03 Million
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $819,824 - $1.42 Million	-752,133 Reduced 6.07%	11,633,700 $12.7 Million
Q3 2021 Nov 12, 2021	SELL	$1.44 - $2.73 $4.88 Million - $9.26 Million	-3,391,633 Reduced 21.5%	12,385,833 $22.5 Million
Q2 2021 Aug 13, 2021	BUY	$2.63 - $3.67 $41.5 Million - $57.9 Million	15,777,466 New	15,777,466 $41.7 Million

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $517M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.